Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors for cardiovascular and neuromuscular diseases. Its first commercial product, MYQORZO (aficamten), is an allosteric and reversible inhibitor of cardiac myosin motor activity approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. The company maintains a pipeline of investigational medicines, including omecamtiv mecarbil for heart failure with reduced ejection fraction, ulacamten for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy. Cytokinetics serves markets in the United States, Europe, China, and Japan, utilizing internal commercial infrastructure in the U.S. and Europe and licensing agreements with Sanofi in China and Bayer in Japan. Founded in 1998, the company specializes in muscle biology and the mechanics of muscle performance, targeting the sarcomere to modulate muscle function and contractility.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage cytokinetics.com
Sector Healthcare IR page ir.cytokinetics.com/overview/default.aspx
Tags
cardiovascular diseases, neuromuscular diseases, hypertrophic cardiomyopathy, heart failure, muscular dystrophy, muscle biology, small molecule drugs, myosin inhibitors, muscle activators, specialty biopharmaceuticals, MYQORZO, aficamten, omecamtiv mecarbil, ulacamten, CK-089, CK-4021586, CK-4015089, Sanofi, Bayer
Press page —

Metrics

Valuation  
Market cap $ 7.287B
Market cap (USD) $ 7.287B
P/E -8.65
PEG —
P/BV -22.69
P/S 64.32
P/OCF -12.74
P/FCF -12.38
Dividend yield —
Turnover / mcap —
Returns  
ROE 119.0%
ROI —
ROIC —
Profit margin -891.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 77
Quality score -37.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004
Revenue 88.039M 18.474M 7.53M 94.588M 70.428M 55.828M 26.868M 31.501M 13.368M 106.407M 28.658M 46.94M 30.648M 7.559M 4M 2.577M — — — — — —
Net profit -784.955M -589.526M -526.244M -388.955M -215.314M -127.29M -121.692M -106.289M -127.79M 16.453M -37.501M -14.646M -33.717M -40.37M -47.86M -49.287M — — — — — —
Free cash flow -534.816M -399.796M -415.749M -310.851M -191.394M -2.109M -93.526M -102.104M -104.636M 35.386M 4.321M -45.947M -8.26M -33.563M -46.038M -45.323M — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004
Share price 63.54 47.04 83.49 45.82 45.58 20.78 10.61 6.32 8.15 12.15 10.46 8.01 6.5 0.61 — 2.92 3.11 2.81 5.39 8.7 — —
Price performance 12m 0.35 -0.44 0.82 0.01 1.19 0.96 0.68 -0.22 -0.33 0.16 0.31 0.23 9.66 — — -0.06 0.11 -0.48 -0.38 — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 24,000 1.11M 2.23M 5.16M 4.42M 51.8M 147,000 1.28M 16.7M 17.8M
↳ YoY growth +4,533.3% +100.6% +131.4% -14.4% +1,072.4% -99.7% +772.8% +1,197.7% +6.7%
↳ 5y CAGR +364.4% -33.3% -10.5% +26.4% +32.1%
Borrowings, current (USD) 2.5M 0.00 2.61M 0.00 0.00 — 958,000 10.1M 11.5M 41.2M
Borrowings, non-current (USD) 27.4M 31.8M 39.8M 45.1M 46.2M 47.4M 63.8M 58.4M 93.2M 246M
Lease liabilities (USD) — — 0.00 6.81M 2.79M 127M 140M 138M 132M 127M
Cash and deposits (USD) 66.9M 125M 42.3M 36.4M 83M 113M 65.6M 113M 94.9M 123M
Right-of-use assets (USD) — — 9.6M — 2.92M 73.1M 82.7M 79M 75.2M 76M
Net debt (borrowings + leases - cash) (USD) -37M -93.4M 157,000 15.4M -34M 61.8M 138M 93.8M 141M 292M
Cash flow detail
Operating cash flow (USD) 37M -102M -101M -90.9M 8.94M -143M -300M -414M -396M -510M
Purchases of property, plant and equipment (USD) -1.6M -2.88M -889,000 -2.62M -11.1M -48.9M -11.3M -1.42M -3.91M -24.8M
Change in receivables (cash effect) (USD) -12,000 -1.09M -1.12M -2.93M 743,000 -47.4M 56.7M -1.14M -15.4M -1.11M
Interest paid (cash effect) (USD) -1.9M -2.13M -2.88M -4.06M -9.62M -9.18M -15.2M -10.3M -26M -22.9M
Income taxes paid (cash effect) (USD) -1,000 -1,000 -1,000 — — — — 0.00 0.00 0.00
Share-based compensation (USD) 7.15M 9.03M 9.76M 10.8M 17.6M 26.8M 47.9M 72.1M 97.8M 112M
Operating cash flow before change in receivables (USD) 37M -101M -100M -88M 8.2M -95.1M -356M -413M -381M -509M
Free cash flow (OCF - PPE - intangibles) (USD) 35.4M -105M -102M -93.5M -2.11M -191M -311M -416M -400M -535M
Income detail
Research and development expense (USD) 59.9M 90.3M 89.1M 86.1M 97M 160M 241M 330M 339M 416M
↳ 5y CAGR +10.0% +20.4% +12.5% +14.2% +15.9% +21.7% +21.7% +29.9% +31.6% +33.8%
Total comprehensive income (USD) 16.4M -128M -106M -122M -128M -216M -392M -523M -587M -787M
Comprehensive income to owners (USD) 16.4M -128M -106M -122M -128M -216M -392M -523M -587M -787M
Reported Mar 5, 2018 Mar 5, 2018 Feb 26, 2021 Mar 4, 2020 May 7, 2021 Feb 25, 2022 Feb 28, 2024 Feb 26, 2026 Feb 26, 2026 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026

MYQORZO_®_ (aficamten) Net Product Revenue of $44.5 Million

Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027

~$1.6 Billion in Cash, Cash Equivalents and Investments as of September 30, 2026

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2026.

“Our third quarter results demonstrate continued strong execution as Cytokinetics enters its next phase of growth as a global specialty cardiology biopharmaceutical company,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In the U.S., the launch of MYQORZO continued to build solid momentum and increased velocity with growing adoption across a broadening base of prescribers. Internationally, we continued to expand access to MYQORZO to bring this important medicine to more patients around the world. Now, with our having presented and published the primary results from ACACIA-HCM, the first positive Phase 3 clinical trial in nHCM, we believe aficamten has the potential to become the first and only cardiac myosin inhibitor approved across the full spectrum of HCM. Building on these key results, we are moving swiftly to seek regulatory approvals in both the U.S. and Europe, important next steps toward achieving our Vision 2030.”

Q3 and Recent Highlights

Cardiac Muscle Programs

MYQORZO**®** (aficamten) (cardiac myosin inhibitor)

  • Continued to drive launch momentum for MYQORZO. Year-to-date (YTD) as of September 30, 2026:

    • Nearly 1,100 unique healthcare providers have prescribed MYQORZO.
    • Over 2,800 patients have been dispensed MYQORZO.
  • MYQORZO received authorization from Health Canada for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients.

  • MYQORZO was granted marketing authorization across the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of symptomatic oHCM of NYHA class II-III in adult patients. The National Institute for Health and Care Excellence (NICE) issued guidance recommending aficamten for use in eligible adult patients in England and Wales. We expect to launch MYQORZO in the United Kingdom in Q4 2026 and in additional countries in 2027.

  • Presented the positive primary results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) in a Hot Line Session at the European Society of Cardiology Congress (ESC) and published in the New England Journal of Medicine. We expect to file a Supplemental New Drug Application (NDA) for nHCM in Q4 2026 and a Type II Variation in the European Union in early 2027.

  • Presented analyses from ACACIA-HCM and SEQUOIA-HCM at the HFSA Annual Scientific Meeting 2026, including two late-breaking presentations, further characterizing the efficacy and safety of aficamten in nHCM and oHCM.

  • Advanced the ongoing clinical trials program for aficamten:

    • Recently initiated ASPEN-HCM, a real-world study of MYQORZO in symptomatic oHCM.
    • Completed conduct of the main study treatment period of CAMELLIA-HCM, a Phase 3 clinical trial of aficamten in Japanese patients with oHCM. CAMELLIA-HCM is being conducted by Bayer in collaboration with Cytokinetics to support potential marketing authorization in Japan.
    • Recently completed conduct of the Japan cohort of ACACIA-HCM.
    • Recently completed conduct of the adolescent cohort of CEDAR-HCM, a clinical trial of aficamten in a pediatric population with symptomatic oHCM. We expect to present topline data in early 2027.
  • Published the following manuscripts:

    • “Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy” in New England Journal of Medicine.
    • “Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy” in Circulation.
    • “Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM” in Circulation.
    • “Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM” in JACC: Heart Failure.

omecamtiv mecarbil (cardiac myosin activator)

  • Continued conduct of COMET-HF, a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction. We expect enrollment to continue through 2027.

ulacamten (cardiac myosin inhibitor)

  • Continued conduct of Cohort 1 of AMBER-HFpEF, a Phase 2 clinical trial of ulacamten in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥ 60%. We expect to complete patient enrollment in Cohort 1 in Q4 of 2026.

CK-4015089 (CK-089, fast skeletal muscle troponin activator)

  • Continued conduct of the second Phase 1 randomized, double-blind, placebo-controlled single ascending dose clinical study of CK-4015089 (CK-089) in healthy human participants.

Pre-Clinical Development and Ongoing Research

  • Achieved a preclinical development milestone under the 2025 research collaboration and license agreement with Accutar Biotech, triggering a $2.5 million payment to Accutar. The collaboration is focused on discovering and developing novel targeted protein degraders for muscle-related diseases.
  • Continued pre-clinical development and research activities directed to additional muscle biology focused programs.

Q3 2026 Financial Results

Cash, Cash Equivalents and Investments

  • As of September 30, 2026, the company had approximately $1.6 billion in cash, cash equivalents and investments compared to $1.7 billion at June 30, 2026.

Revenues

  • Total revenues for the third quarter of 2026 were $47.6 million, compared to $1.9 million for the same period in 2025. Total revenues in the third quarter of 2026 include:
    • $44.5 million MYQORZO net product revenue, inclusive of $43.1 million from the U.S. and $1.4 million from Europe reflecting product revenue in Germany, and
    • $3.1 million in collaboration revenue compared to $1.9 million for the same period in 2025.

Research and Development (R&D) Expenses

  • R&D expenses for the third quarter of 2026 were $99.3 million, which included $15.1 million of non-cash stock-based compensation expense, compared to $97.3 million for the same period in 2025, which included $15.1 million of non-cash stock-based compensation expense. The increase was primarily due to higher clinical trial activity and higher personnel-related costs.

Selling, General and Administrative (SG&A) Expenses

  • SG&A expenses for the third quarter of 2026 were $113.1 million, which included $19.6 million of non-cash stock-based compensation expense, compared to $69.5 million for the same period in 2025, which included $15.6 million of non-cash stock-based compensation expense. The increase was primarily due to external costs associated with the commercial launch of MYQORZO and higher personnel-related costs, including stock-based compensation.

Cost of Goods Sold

  • Cost of goods sold related to MYQORZO for the third quarter of 2026 was ($0.5) million and reflects a credit related to drug supply optimization activities.

Collaboration Cost of Revenues

  • Collaboration cost of revenues for the third quarter of 2026 was $2.7 million, compared to $1.9 million for the same period in 2025. Collaboration cost of revenues includes cost reimbursements as well as costs incurred in connection with manufacturing drug supplies for collaboration partners.

Net Income (Loss)

  • Net loss for the third quarter of 2026 was $190.1 million, or $(1.37) per share, basic and diluted, compared to a net loss of $306.2 million, or $(2.55) per share, basic and diluted, for the same period in 2025.

2026 Financial Guidance

The company is reaffirming its full year 2026 financial guidance:

GAAP combined R&D and SG&A Expense $860 million to $890 million
Non-cash stock-based compensation expense included in GAAP combined R&D and SG&A Expense $140 million to $130 million

The financial guidance does not include the effect of GAAP adjustments as may be caused by events that occur subsequent to publication of this guidance including, but not limited to, Business Development activities.

Conference Call and Webcast Information

Members of Cytokinetics’ senior management team will review the company’s third quarter 2026 results on a conference call today at 4:30 PM Eastern Time. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com or directly at the following link: Cytokinetics Q3 2026 Earnings Conference Call . An archived replay of the webcast will be available via Cytokinetics’ website for six months.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube .

Disclaimer 

Omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements in this press release other than statements of historical fact are forward-looking statements. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such statements include, but are not limited to, statements, express or implied, relating to our plans to submit a Supplemental NDA for aficamten in non-obstructive HCM in the fourth quarter of 2026 and a Type II Variation in the European Union in early 2027, and the timing and outcome of any related regulatory review; our belief that aficamten has the potential to become the first and only cardiac myosin inhibitor approved across the full spectrum of HCM; the continued commercial launch of MYQORZO in the U.S., including launch momentum, prescriber adoption, patient uptake, market acceptance and net product revenue; our plans to launch MYQORZO in additional markets outside the U.S., including our expectation to launch in the United Kingdom in the fourth quarter of 2026 and in additional countries in 2027, and the timing and outcome of pending regulatory, pricing and reimbursement reviews in Switzerland, Hong Kong, Taiwan and other jurisdictions; our or our partners’ research and development and commercial readiness activities, including the initiation, conduct, design, enrollment, progress, continuation, completion, timing and results of any of our clinical trials, including ACACIA-HCM (including its Japan cohort), CAMELLIA-HCM, ASPEN-HCM, COMET-HF, AMBER-HFpEF and CEDAR-HCM and our clinical study of CK-089; our expectations to present topline data from the adolescent cohort of CEDAR-HCM in early 2027, to complete patient enrollment in Cohort 1 of AMBER-HFpEF in the fourth quarter of 2026 and for COMET-HF to continue enrollment through 2027; the clinical meaningfulness, persuasiveness, or interpretation of the results of MAPLE-HCM, SEQUOIA-HCM, ACACIA-HCM or any of our other clinical trials, including for purposes of regulatory approval, labeling, or market acceptance, the results of long-term, secondary or exploratory analyses, our ability to announce the results of any of our clinical trials by any particular date, the timing of interactions with FDA or any other regulatory authorities in connection with any of our drug candidates and the outcomes of such interactions; statements related to our receipt of regulatory approvals for aficamten in any ex-US jurisdiction, including Japan, for any indication and by any particular date, statements relating to the potential patient population who could benefit from aficamten, omecamtiv mecarbil, ulacamten, CK-089 or any of our other drug candidates; statements related to the potential approval and launch of MYQORZO in non-obstructive HCM; our research collaboration with Accutar Biotech and our other pre-clinical research activities, including any future milestone payments under such collaboration; our strategic goals, including our Vision 2030; our full year 2026 financial guidance, including our combined GAAP research and development and selling, general and administrative expense guidance and related non-cash stock-based compensation expense estimates, and the assumptions underlying such guidance; statements relating to our ability to receive additional capital or other funding, including, but not limited to, our ability to meet any of the conditions relating to or to otherwise secure additional loan disbursements under any of our agreements with entities affiliated with Royalty Pharma or additional milestone payments from Sanofi or Bayer in connection with our collaborations for aficamten in China or Japan respectively; statements relating to our operating expenses or cash utilization for the remainder of 2026 or any other period, and statements relating to our cash balance at any particular date or the amount of cash runway such cash balances represent at any particular time. Such statements are based on management's current expectations and assumptions, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: risks related to the commercialization of MYQORZO, including the degree of market acceptance among physicians, patients and payors, the availability of adequate coverage, pricing and reimbursement in the U.S. and other markets, our ability to maintain and expand our commercial capabilities and those of our partners, and fluctuations in net product revenue from period to period; competition from other cardiac myosin inhibitors and other existing or future therapies; the FDA or foreign regulatory agencies may not accept for review, or may delay, limit or deny approval of, our Supplemental NDA, Type II Variation or other marketing applications, or may require additional clinical trials or impose restrictive labeling or post-marketing requirements; the identification of new safety signals or adverse events relating to MYQORZO or our drug candidates as they are used more broadly; our dependence on third-party manufacturers and suppliers and on our collaboration and commercial partners, including Bayer and Sanofi, to perform their obligations; Cytokinetics’ need for additional funding and such additional funding may not be available on acceptable terms, if at all; our outstanding indebtedness and payment obligations, including under our agreements with entities affiliated with Royalty Pharma; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials; Cytokinetics may incur unanticipated research and development, commercial and other costs; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; our ability to obtain, maintain and enforce intellectual property protection; and changes in laws, regulations or government policies affecting drug pricing, reimbursement, tariffs or trade, as well as general economic, market and geopolitical conditions. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission, particularly under the caption “Risk Factors” in Cytokinetics’ Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent Quarterly Reports on Form 10-Q, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Except as required by law, Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S., European Union, United Kingdom and Canada.

November 3, 2026

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in November:

  • Stifel 2026 Healthcare Conference: Fireside chat on Tuesday, November 10, 2026 at 1:20 PM Eastern Time in New York, NY.
  • UBS Global Biopharma Conference 2026: Fireside chat on Monday, November 16, 2026 at 10:40 AM Greenwich Mean Time in London, England.
  • Jefferies Global Healthcare Conference: Fireside chat on Tuesday, November 17, 2026 at 11:00 AM Greenwich Mean Time in London, England.
  • 9****th Annual Evercore Healthcare Conference: Fireside chat on Monday, November 30, 2026 at 3:00 PM Eastern Time in Coral Gables, FL.

Interested parties may access the live webcasts of the fireside chats by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com . The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the event.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube .

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union, the United Kingdom and Canada.

November 2, 2026

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Oral Abstract presentations and one poster presentation, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions, held in collaboration with the American Heart Association Scientific Sessions, taking place in Chicago, IL, November 6, 2026.

Late-Breaking Oral Abstracts

Title: Effect of Aficamten on Cardiac Structure and Function in Nonobstructive Hypertrophic Cardiomyopathy: The ACACIA-HCM CMR Study****Presenter: Ahmad Masri, M.D., M.S., Associate Professor of Medicine, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: Friday, November 6, 2026
Session Title: Session 4 - Late Breaking Oral Abstracts
Session Time: 2:15 PM – 3:15 PM CT
Presentation Time: 2:30 PM – 2:40 PM CT
Location: Room S406a

Title: Effect of Aficamten on Patient-Reported Health Status in Non-Obstructive Hypertrophic Cardiomyopathy
Presenter: Michael E. Nassif, M.D., Cardiologist, Saint Luke’s Mid America Heart Institute
Date: Friday, November 6, 2026
Session Title: Session 4 – Late Breaking Oral Abstracts
Session Time: 2:15 PM - 3:15 PM CT
Presentation Time: 2:45 PM -2:55 PM CT
Location: Room S406A

Poster Presentation

Title: Left Ventricular Systolic Dysfunction in Long-Term Aficamten Therapy for Obstructive HCM: A FOREST-HCM Analysis
Presenter: Daniele Massera, M.D., Director, Hypertrophic Cardiomyopathy Program, NYU Langone Health, Assistant Professor, Department of Medicine, NYU Grossman School of Medicine
Date: November 6, 2026
Session Title: Poster Reception
Session Time: 5:30 PM - 6:30 PM CT
Presentation Time: 5:30 PM - 6:30 PM CT
Location: Room S406B

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube .

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to our ability to obtain regulatory approval for aficamten in nonobstructive hypertrophic cardiomyopathy in any jurisdiction by any particular date, if ever, the number of patients comprising the eligible treatment population for aficamten, or market acceptance of aficamten for the treatment of nonobstructive hypertrophic cardiomyopathy. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union, the United Kingdom and Canada.

Prompts

Cytokinetics, Incorporated (ticker CYTK), listed in United States.

ETFs Holding Cytokinetics, Incorporated

ETF Weight in ETF Shares Market value As of
HRTS 3.53% 27,649 $ 1.961M Aug 31, 2026
LFSC 3.50% 62,243 $ 4.414M Aug 31, 2026
TMED 1.69% 4,564 $ 388.807K Jun 30, 2026
GDOC 1.58% 4,355 $ 308.813K Aug 31, 2026
BMED 1.07% 2,888 $ 153.555K Nov 16, 2026
GSC 0.98% 38,699 $ 2.744M Aug 31, 2026
TCAF 0.79% 1,605,427 $ 85.361M Nov 17, 2026
TCAL 0.62% 38,242 $ 2.033M Nov 17, 2026
FSEV 0.60% 470 $ 40.039K Jun 30, 2026
MKTN short -0.49% -6,115 $ -520.937K Jun 30, 2026
ORR 0.38% 26,687 $ 1.38M Nov 18, 2026
RUSC 0.36% 3,329 $ 283.598K Jun 30, 2026
SCDS 0.33% 585 $ 30.215K Nov 17, 2026
FESM 0.33% 222,902 $ 18.989M Jun 30, 2026
RESM 0.32% 139 $ 11.841K Jun 30, 2026
FTKI 0.29% 1,410 $ 74.97K Nov 16, 2026
TMSL 0.25% 79,499 $ 6.773M Jun 30, 2026
FSCC 0.21% 10,987 $ 779.088K Aug 31, 2026
FFLG 0.20% 15,469 $ 1.193M Jul 31, 2026
VFMO 0.15% 40,097 $ 2.843M Aug 31, 2026
NBCR 0.12% 14,569 $ 1.033M Aug 31, 2026
SMDX 0.12% 2,953 $ 157.011K Nov 17, 2026
FSEG 0.11% 76 $ 6,474.44 Jun 30, 2026
FSML 0.11% 1,622 $ 138.178K Jun 30, 2026
ESSC 0.10% 466 $ 35.943K Jul 31, 2026
JMEE 0.09% 49,000 $ 2.531M Nov 17, 2026
AVIE 0.07% 220 $ 11.697K Nov 16, 2026
MSSM 0.05% 5,279 $ 374.334K Aug 31, 2026
IALT short -0.04% -65,656 $ -3.491M Nov 16, 2026
AVSU 0.01% 570 $ 30.307K Nov 16, 2026
AVLC 0.01% 2,130 $ 113.252K Nov 16, 2026
AVUQ 0.01% 557 $ 29.616K Nov 16, 2026
NTRL short 0.00% -2,416 $ 0.00 Nov 16, 2026